The British Business Bank is a government-owned development bank created to increase the supply and diversity of finance for smaller businesses in the UK.
The Falmouth based marine engineering firm raised the capital from backers including the British Business Bank and Welsh Ministers to support its Morlais project.
"This latest funding round is crucial to the next stage of this project, allowing us to build a demonstrator that includes a number of turbine improvements and developments. We’re delighted that our investors are backing us on this journey to be part of such an important step in tidal energy infrastructure. FSE in particular has been with us for a several years and it’s exciting to be moving towards an operational project at Morlais."
The financing will be used to expand technical teams and accelerate the commercialisation of its proteomics platform.
"Portal Biotech’s technology offers unprecedented capabilities in protein identification and characterisation, providing unmatched detail on protein structure and modifications at the single-molecule level on accessible desktop instruments that bring this state-of-the-art characterisation to any lab. These powerful advances are essential for accelerating drug discovery and enhancing diagnostic precision, positioning Portal Biotech as the frontrunner in the race to unlock the full potential of protein sequencing."
The Cardiff-based space tech startup has secured the largest Series A round in the UK sector to advance its in-orbit manufacturing missions.
"This funding marks a significant milestone-not just for Space Forge, but for the entire space economy. With the backing of our investors, we're accelerating our mission to make space a practical and accessible platform for industrial-scale manufacturing. Our upcoming launches will prove that the future of materials innovation lies beyond Earth, helping us build a more secure, sustainable, and technologically advanced world."
Twin Path Ventures led the seed financing for the Belfast biotechnology firm to accelerate its preclinical discovery programmes.
"Ten years ago, I began combining financial modeling expertise with computational biology to create a drug discovery platform. Evolution has spent billions of years perfecting natural defense mechanisms, and now we’re using AI to unlock this wisdom. This isn’t just professional for me; my father died from a drug-resistant infection our healthcare system couldn’t treat. At Queen’s, I built AMPLY to tackle deadly diseases differently, creating technology that will save lives when current treatments fail."
-20webclip.png)
